News
-
-
-
COMMUNIQUÉ DE PRESSE
MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development
MIRA acquires SKNY Pharmaceuticals, enhancing pipeline with next-gen oral therapeutic for obesity and smoking. Strategic move to address leading causes of preventable death -
-
-
COMMUNIQUÉ DE PRESSE
MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain
MIRA Pharmaceuticals introduces topical Ketamir-2 for neuropathic and inflammatory pain, expanding pain management portfolio with innovative targeted approach -
-
-
COMMUNIQUÉ DE PRESSE
MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain
MIRA Pharmaceuticals, Inc. announces Phase 1 clinical trial initiation for Ketamir-2, a novel oral ketamine analog targeting neuropathic pain, in Israel. Study aims to evaluate safety, tolerability, and pharmacokinetics -
